CLINICAL_TRIALS
ClinicalTrials.gov record update
Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00185211
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:34.469748+00:00
- Published At
- 2010-11-30T00:00:00+00:00
- Record Updated At
- 2013-12-30
- Results Posted At
- 2010-11-30
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Multiple Sclerosis"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-12-30"- protocolSection.identificationModule.nctId
"NCT00185211"- protocolSection.identificationModule.officialTitle
"Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 \u00b5g) Interferon Beta-1b (Betaferon\u00ae / Betaseron\u00ae) Given Subcutaneously Every Other Day for at Least 36 Months."- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2010-11-30"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.